The company would initially produce syrup type preparation of Tamiflu, meant for children. Presently, the drug company is involved in packaging and sales of the anti-bird flu drug following production at the Swiss unit. Prior to this, the key ingredients of the drug are approved by Germany. Domestic production of drug is hoped to reduce the associated cost by a significant margin.
After a careful analysis of the profitability, the company would further decide regarding manufacture of the bird flu drug in a capsule form. There is a fear that rapid spread of a bird flu epidemic could lead to a shortage of bird flu vaccine supply. In order to increase preparedness against bird flu during the current bird flu season, the company has already acquired sufficient supplies to treat more than 12 million people.